AR053122A1 - Monohidrato de di-s-camsilato de 5((2r,5s)-5-metil-4-propilmorfolin-2-il)piridin-2-amina, agonista de dopamina - Google Patents

Monohidrato de di-s-camsilato de 5((2r,5s)-5-metil-4-propilmorfolin-2-il)piridin-2-amina, agonista de dopamina

Info

Publication number
AR053122A1
AR053122A1 ARP060100417A ARP060100417A AR053122A1 AR 053122 A1 AR053122 A1 AR 053122A1 AR P060100417 A ARP060100417 A AR P060100417A AR P060100417 A ARP060100417 A AR P060100417A AR 053122 A1 AR053122 A1 AR 053122A1
Authority
AR
Argentina
Prior art keywords
methyl
propilmorfolin
monohidrate
piridin
camsilate
Prior art date
Application number
ARP060100417A
Other languages
English (en)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR053122A1 publication Critical patent/AR053122A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)

Abstract

Procedimientos para la preparacion, intermedios, composiciones que contienen esta sal y a los usos de esta sal para disfuncion sexual y trastornos neurosiquiátricos o neurodegenerativos. Reivindicacion 1: di-S-camsilato de 5-[(2R,5S)-5-metil-4- propilmorfolin-2-il]piridin-2-amina. Reivindicacion 12: Un compuesto de formula (7) y sus sales y solvatos farmacéuticamente aceptables.
ARP060100417A 2005-02-07 2006-02-06 Monohidrato de di-s-camsilato de 5((2r,5s)-5-metil-4-propilmorfolin-2-il)piridin-2-amina, agonista de dopamina AR053122A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502509.3A GB0502509D0 (en) 2005-02-07 2005-02-07 Novel salt form of a dopamine agonist

Publications (1)

Publication Number Publication Date
AR053122A1 true AR053122A1 (es) 2007-04-25

Family

ID=34355919

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100417A AR053122A1 (es) 2005-02-07 2006-02-06 Monohidrato de di-s-camsilato de 5((2r,5s)-5-metil-4-propilmorfolin-2-il)piridin-2-amina, agonista de dopamina

Country Status (26)

Country Link
US (1) US7498329B2 (es)
EP (1) EP1848709B1 (es)
JP (1) JP4157158B2 (es)
KR (1) KR100997033B1 (es)
CN (1) CN101115737B (es)
AR (1) AR053122A1 (es)
AT (1) ATE509924T1 (es)
AU (1) AU2006211033A1 (es)
BR (1) BRPI0608149A2 (es)
CA (1) CA2595815C (es)
DO (1) DOP2006000030A (es)
ES (1) ES2364345T3 (es)
GB (1) GB0502509D0 (es)
GT (1) GT200600040A (es)
HN (1) HN2006004827A (es)
IL (1) IL184395A0 (es)
MX (1) MX2007008462A (es)
NL (1) NL1031087C2 (es)
NZ (1) NZ556292A (es)
PA (1) PA8662001A1 (es)
PE (1) PE20061034A1 (es)
RU (1) RU2393153C2 (es)
TW (1) TWI314930B (es)
UY (1) UY29365A1 (es)
WO (1) WO2006082511A1 (es)
ZA (1) ZA200605491B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8522799B2 (en) * 2005-12-30 2013-09-03 Lam Research Corporation Apparatus and system for cleaning a substrate
KR100913791B1 (ko) * 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
KR102108226B1 (ko) 2010-02-12 2020-05-08 화이자 인코포레이티드 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체
WO2016067043A1 (en) 2014-10-31 2016-05-06 Indivior Uk Limited Dopamine d3 receptor antagonists compounds
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
RU2622018C1 (ru) * 2016-06-16 2017-06-08 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Быстро растворяющаяся трансбуккальная плёнка для лечения депрессивных расстройств, тревоги и расстройств адаптации

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP3889775B2 (ja) * 2002-12-10 2007-03-07 ファイザー・インク Ｉ．ａ．性機能障害の治療においてドパミンアゴニストとして使用するためのモルホリン誘導体
CA2567935C (en) * 2004-05-27 2009-10-27 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists

Also Published As

Publication number Publication date
CA2595815A1 (en) 2006-08-10
CN101115737A (zh) 2008-01-30
MX2007008462A (es) 2007-07-25
US20060183740A1 (en) 2006-08-17
EP1848709B1 (en) 2011-05-18
NL1031087A1 (nl) 2006-08-08
BRPI0608149A2 (pt) 2009-11-10
US7498329B2 (en) 2009-03-03
GT200600040A (es) 2007-01-12
IL184395A0 (en) 2007-10-31
CN101115737B (zh) 2010-12-01
AU2006211033A1 (en) 2006-08-10
PE20061034A1 (es) 2006-10-19
DOP2006000030A (es) 2006-08-15
RU2007130150A (ru) 2009-03-20
KR100997033B1 (ko) 2010-11-26
JP2008529997A (ja) 2008-08-07
TW200639164A (en) 2006-11-16
UY29365A1 (es) 2006-10-02
HN2006004827A (es) 2010-06-09
EP1848709A1 (en) 2007-10-31
NL1031087C2 (nl) 2007-01-19
PA8662001A1 (es) 2006-09-08
WO2006082511A1 (en) 2006-08-10
KR20070094647A (ko) 2007-09-20
ZA200605491B (en) 2008-09-25
JP4157158B2 (ja) 2008-09-24
NZ556292A (en) 2010-10-29
ATE509924T1 (de) 2011-06-15
RU2393153C2 (ru) 2010-06-27
ES2364345T3 (es) 2011-08-31
GB0502509D0 (en) 2005-03-16
CA2595815C (en) 2010-07-27
TWI314930B (en) 2009-09-21

Similar Documents

Publication Publication Date Title
AR053122A1 (es) Monohidrato de di-s-camsilato de 5((2r,5s)-5-metil-4-propilmorfolin-2-il)piridin-2-amina, agonista de dopamina
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CL2004000655A1 (es) Compuestos derivados de piperidin-2-ona 1,6-disustituidos, sus sales, composicion farmaceutica, agonistas del receptor ep4; uso de los compuestos para tratar hipertension ocular, glaucoma.
GT200500309A (es) Derivados de sulfonilbencilimidazol
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
UY29601A1 (es) Arilpirazoles sustituidos
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
RS52526B (en) OXADIAZOL DERIVATIVES AND THEIR USE AS A POTENTIAL OF METABOTROPIC GLUTAMATE RECEPTORS-842
CR7261A (es) Derivados de diarilcicloalquilo, procedimiento para su preparacion y su utilizacion como agentes activadores del ppar
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
AR053334A1 (es) Pirazolilcarboxanilidas
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
ECSP088296A (es) Compuestos terapéuticos
UY29893A1 (es) Derivados de pirazina
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
PA8570701A1 (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparacion
BRPI0615898B8 (pt) composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
ECSP077163A (es) Compuestos para el tratamiento de trastornos inflamatorios
UY30460A1 (es) Compuestos terapéuticos
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7

Legal Events

Date Code Title Description
FB Suspension of granting procedure